Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Neuropharmacol ; 27(5): 219-22, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15602102

RESUMEN

Serotonin syndrome (SS) is a potentially fatal complication of the combined use of agents that enhance serotonin activity. Bupropion inhibits noradrenaline and dopamine reuptake with milder effects on serotonergic activity. Although regarded as a potential causative agent for SS, no cases have been reported in the medical literature. A 62-year-old woman treated with therapeutic dosages of bupropion and sertraline for depression for the previous 3 weeks presented with upper extremity myoclonic jerks, clumsiness, and gait difficulties with fluctuating symptoms of confusion, forgetfulness, and the alternation of agitation and lethargy. Symptoms were interpreted as an aggravation of depression and venlafaxine was added. The clinical picture progressed to alteration of consciousness and dysautonomia. After admission, medications were discontinued and she was started on cyproheptadine and clonazepam with gradual improvement and complete resolution of symptoms. This is a rare report of SS related to the association of bupropion and selective serotonin reuptake inhibitors (SSRIs). It also illustrates the potential for misinterpretation of the earliest manifestations of SS as signs of aggravation of the patient's underlying condition. The role of bupropion in SS is possibly related to its well-established specific inhibition of the cytochrome P450 2D6 pathway, increasing blood levels of SSRIs and tricyclic antidepressants.


Asunto(s)
Antidepresivos de Segunda Generación/efectos adversos , Bupropión/efectos adversos , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Síndrome de la Serotonina/etiología , Ciproheptadina/uso terapéutico , Interacciones Farmacológicas , Femenino , Fluoxetina/efectos adversos , Humanos , Persona de Mediana Edad , Antagonistas de la Serotonina/uso terapéutico , Síndrome de la Serotonina/psicología , Sertralina/efectos adversos
2.
J Psychoactive Drugs ; 30(4): 367-9, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9924842

RESUMEN

The Amazonian psychoactive plant beverage ayahuasca has attracted increasing interest in recent years. Little attention has been given, however, to potentially dangerous interactions with other drugs. In particular, the interaction between the potent monoamine oxidase-inhibiting harmala alkaloids in ayahuasca and the selective serotonin reuptake inhibitor (SSRI) class of antidepressants may induce a serotonin syndrome with potentially grave outcome. Caution is advised when combining ayahuasca with certain pharmaceutical drugs.


Asunto(s)
Plantas Medicinales/efectos adversos , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Síndrome de la Serotonina/inducido químicamente , Adulto , Brasil , Interacciones Farmacológicas , Fluoxetina/efectos adversos , Interacciones de Hierba-Droga , Humanos , Masculino , Plantas Medicinales/química , Síndrome de la Serotonina/psicología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA